

**Freedom of Information Act 2000 – Request Reference FoI/23/656**  
**Asthma Treatment**

**Q1. How many patients have been treated (for any condition) in the last 4 months with:**

- Benralizumab: 71
- Dupilumab: 115
- Omalizumab: 52
- Reslizumab: 0
- Mepolizumab: 44
- Tezepelumab: 42

**Q2. Of the patients treated in the last 4 months with any of the above products, please provide the number of patients by the following age groups:**

- Age 6–11: 8
- Age 12–17: 21
- Age 18 and above: 286

**Q3. How many patients have been treated in the last 4 months by the Respiratory Medicines Department ONLY with:**

- Dupilumab: 28
- Omalizumab: 18

All of the above figures reflect data available from 1 August 2023 to 30 November 2023.